Petrovax Pharm is selling products as part of a joint partnership with LLC Vaga Pharm, a medication supplier on the Armenian market.

The Vladimir Potanin Foundation announced the results of the grant competition, which started in January 2014 in the framework of the Olympic Scholarships Program. The purpose of the program is to help future sports managers to get a quality professional education in the Russian International Olympic University (RIOU) in Sochi.

According to Orange Book, a regular report by Synergy Research Group, Petrovax Pharm has become one of the Top 5 companies by number of clinical trials started in Q2 2014 in the Russian pharmaceuticals market.

The immunobiological production unit of NPO Petrovax Pharm, a Russian pharmaceutical company, has produced more than 2.5 mln doses of Prevenar 13, a 13-valent conjugate pneumococcal vaccine, in easy to use disposable auto injectors. More than 5 mln doses are planned to be produced by the end of 2014.

On March 26, 2014, NPO Petrovax Pharm ran a media tour for key business and industry journalists at the Company's production site in the Podolsk District of Moscow Region. The journalists were taken on a tour around the unique facility where 13-valent conjugate pneumococcal vaccine is produced.